Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Intervention Better Than Drugs For Heart Attack, Registry Analysis Says

This article was originally published in The Gray Sheet

Executive Summary

Registry data from 26,205 patients treated for acute myocardial infarction within 15 hours of symptom onset indicate that percutaneous coronary intervention (PCI) is superior to medical management at restoring normal blood flow to the heart

You may also be interested in...



Study Says No To Angioplasty Days After A Heart Attack

A study presented at an American Heart Association (AHA) conference last week concludes that angioplasty and stenting are of no value to heart attack patients if used three days or later following the event, even if the impacted artery remains blocked

Study Says No To Angioplasty Days After A Heart Attack

A study presented at an American Heart Association (AHA) conference last week concludes that angioplasty and stenting are of no value to heart attack patients if used three days or later following the event, even if the impacted artery remains blocked

When Less Is More: Costly Interventions For ACS Patients Critiqued In JAMA

Acute myocardial infarction care in the U.S. could benefit from less of a focus on invasive cardiac interventions and more reliance on established, inexpensive medical management strategies, researchers suggest in the March 16 issue of JAMA

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel